FDA Approves ANDA for Bupropion Hydrochloride by Yichang Humanwell
The FDA has granted approval for ANDA220529 for Bupropion Hydrochloride submitted by Yichang Humanwell.
Focal Asset
FDA
Indication
Neurology / Antidepressant
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of Yichang Humanwell's ANDA for Bupropion Hydrochloride introduces a new competitor in the antidepressant market, which could impact pricing and market share for existing products. Portfolio teams must evaluate the competitive landscape and adjust strategies accordingly.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and any subsequent pricing strategies from Yichang Humanwell.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.